GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Net Income Including Noncontrolling Interests

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Net Income Including Noncontrolling Interests : $0.09 Mil (TTM As of Dec. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Parnell Pharmaceuticals Holdings's Net Income Including Noncontrolling Interests for the six months ended in Dec. 2018 was $0.09 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2018 was $0.09 Mil.

Parnell Pharmaceuticals Holdings Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Net Income Including Noncontrolling Interests Chart

Parnell Pharmaceuticals Holdings Annual Data
Trend Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial -16.23 -9.96 -15.94 -17.68 0.09

Parnell Pharmaceuticals Holdings Semi-Annual Data
Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial -16.23 -9.96 -15.94 -17.68 0.09

Parnell Pharmaceuticals Holdings Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2018 was $0.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parnell Pharmaceuticals Holdings Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
OWCP CXUS CANB CNABQ LITH APPB GSRX PCYN EVIO GENH ZTS TSE:4502 XTER:MRK HKSE:03692 TSE:4523 SZSE:000661 TSE:4507 SZSE:000538 NSE:SUNPHARMA SZSE:300601
Traded in Other Exchanges
N/A
Address
476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015
Website
https://www.parnell.com
Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.